Alembic Pharmaceuticals Share Price Today | Stock Price & Alembic Pharmaceuticals Share Screener
As of November 19, 2026, the live Alembic Pharmaceuticals share price (NSE: APLLTD) is ₹1,049.60 on NSE and ₹1,048.75 on BSE, up 0.50% from the previous close, with shares trading between ₹1,038.50 and ₹1,054.25 in today's trading session, and a 52-week range of ₹646.55–₹1,057.10. Track Alembic Pharmaceuticals marketcap in USD to gauge the company's total market size. Use the Alembic Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Alembic Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹1,874 and net income of ₹202, with EBITDA of ₹230, an operating margin of 11.0% and a profit margin of 10.8%.
Alembic Pharmaceuticals Share Price Chart
Track the current stock price of Alembic Pharmaceuticals with an interactive chart. Analyse APLLTD share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Alembic Pharmaceuticals stock quote in one place.
The quote of ₹1,049.60 sits between the 52-week low of ₹646.55 and the 52-week high of ₹1,057.10, and the latest session moved 0.50% from the previous close.
Alembic Pharmaceuticals Company Profile - Fundamental Screener
Screen Alembic Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for APLLTD shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with C R Amin listed as chairperson or CEO, and it trades under ISIN INE901L01018.
Business Overview
Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across...more
Company Details
Classification
Identifiers and Leadership
Alembic Pharmaceuticals Balance Sheet Screener
Screen APLLTD balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹8,763, up from ₹7,773 in 2025.
Latest statistics put total assets at ₹8,763 and shareholder funds at ₹5,669, with a leverage ratio of 0.25.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 8,763 | 7,773 | 6,446 | 6,183 | 7,122 | 6,709 | 5,989 | 4,778 | 3,941 | 2,689 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 3,081 | 2,524 | 2,547 | 2,398 | 1,798 | 1,788 | 1,552 | 1,159 | 993 | 799 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 500 | 171 | 172 | 175 | 168 | 361 | 1,047 | 570 | 576 | 94 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 5,669 | 5,190 | 4,818 | 4,371 | 5,238 | 5,067 | 3,190 | 2,718 | 2,220 | 1,902 |
| Share Capital | 39 | 39 | 39 | 39 | 39 | 39 | 38 | 38 | 38 | 38 |
| Reserves & Surplus | 5,636 | 5,152 | 4,779 | 4,331 | 5,198 | 5,028 | 3,182 | 2,681 | 2,182 | 1,865 |
Alembic Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Alembic Pharmaceuticals income statement and profit fundamentals. Analyze APLLTD quarterly results. Alembic Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹1,874 and net profit was ₹202, equal to earnings per unit of ₹10.31, at an operating margin of 11%.
In that period expenses were ₹1,645, interest cost ₹23 and tax ₹-83. The next period listed, 2026-Jun, shows revenue of ₹2,165 and net profit of ₹172.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 1,874 | 2,165 | 2,619 | 1,784 | 1,717 | 1,919 | 1,892 | 1,521 | 1,564 | 1,678 | 1,703 | 1,407 | 1,498 | 1,605 | 1,634 |
| Expenses | 1,645 | 1,818 | 2,042 | 1,498 | 1,430 | 1,595 | 1,627 | 1,257 | 1,325 | 1,409 | 1,433 | 1,203 | 1,288 | 1,387 | 1,364 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 230 | 347 | 577 | 286 | 287 | 324 | 265 | 263 | 239 | 270 | 270 | 205 | 210 | 218 | 269 |
| Operating Profit % | 11.00% | 15.00% | 22.00% | 15.00% | 16.00% | 17.00% | 13.00% | 17.00% | 15.00% | 15.00% | 15.00% | 14.00% | 13.00% | 13.00% | 16.00% |
| Depreciation | 89 | 98 | 101 | 69 | 74 | 76 | 80 | 70 | 69 | 71 | 70 | 74 | 66 | 68 | 69 |
| Interest | 23 | 28 | 38 | 25 | 24 | 24 | 23 | 11 | 13 | 19 | 22 | 14 | 14 | 16 | 15 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 119 | 222 | 438 | 192 | 190 | 224 | 162 | 183 | 157 | 180 | 178 | 116 | 130 | 135 | 185 |
| Tax | -83 | 50 | 104 | 35 | 37 | 40 | 30 | 5 | 23 | 27 | 40 | -36 | 9 | -2 | 4 |
| Net Profit | 202 | 172 | 334 | 157 | 154 | 184 | 132 | 178 | 135 | 153 | 138 | 153 | 121 | 137 | 180 |
| EPS | 10.31 | 8.80 | 17.05 | 7.98 | 7.85 | 9.40 | 6.76 | 9.07 | 6.84 | 7.79 | 7.01 | 7.76 | 6.14 | 6.95 | 9.23 |
Alembic Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen APLLTD cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹783, and net cash flow was an inflow of ₹113.
Over the same period, investing activities used ₹506 and financing activities used ₹164.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 783 | 88 | 803 | 724 | 552 | 1,463 | 449 | 812 | 312 | 329 |
| Investing Activities | -506 | -568 | -321 | -448 | -372 | -840 | -731 | -756 | -884 | -486 |
Financing and Net Cash | ||||||||||
| Financing Activities | -164 | 444 | -438 | -262 | -217 | -597 | 155 | 59 | 503 | -129 |
| Net Cash Flow | 113 | -37 | 45 | 14 | -37 | 26 | -127 | 115 | -69 | -286 |
Alembic Pharmaceuticals Shareholding Pattern Screener
See Alembic Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Alembic Pharmaceuticals promoter holding and ownership changes for APLLTD on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 69.74%, foreign institutions 4.25%, domestic institutions 16.18% and the public 6.86%, spread across 86,432 shareholders.
The shareholder count was 86,432 in 2026-Mar, compared with 86,796 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 69.74% | 69.87% | 69.87% | 69.67% | 69.67% | 69.74% | 69.74% | 69.61% |
Institutional Investors | ||||||||
| FII Holding | 4.25% | 4.18% | 4.55% | 3.94% | 3.96% | 4.05% | 4.24% | 4.46% |
| DII Holding | 16.18% | 15.94% | 15.43% | 16.43% | 16.46% | 16.30% | 16.17% | 15.38% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 6.86% | 6.97% | 7.00% | 7.07% | 7.01% | 6.93% | 6.87% | 7.41% |
| Other Holding | 2.96% | 3.03% | 3.15% | 2.88% | 2.89% | 2.99% | 2.98% | 3.14% |
| Shareholder Count | 86,432 | 86,796 | 86,532 | 91,336 | 89,013 | 89,969 | 87,000 | 76,567 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Alembic Pharmaceuticals. Alembic Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹12.00 per unit for 2026-March, a yield of 1.16%, compared with ₹11.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹12.00, ₹11.00 and ₹11.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹12.00 | 1.16% |
| 2025-March | ₹11.00 | 1.66% |
| 2024-March | ₹11.00 | 1.18% |
| 2023-March | ₹8.00 | 0.81% |
| 2022-March | ₹10.00 | 2.13% |
| 2021-March | ₹14.00 | 1.89% |
| 2020-March | ₹10.00 | 1.04% |
| 2019-March | ₹5.50 | 1.03% |
| 2018-March | ₹4.00 | 0.74% |
| 2017-March | ₹4.00 | 0.73% |
Alembic Pharmaceuticals Stock Index Membership - Nifty & Sensex
See which indices include Alembic Pharmaceuticals stock. Check APLLTD index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 16 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.
Complete Index List
Alembic Pharmaceuticals Market Events Screener - Corporate Actions
Get Alembic Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Alembic Pharmaceuticals stock events that may affect APLLTD share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 4, 2026, with a record date of November 4, 2026.
It is followed by Annual General Meeting dated August 5, 2026 and Quarterly Result Announcement dated August 4, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-04 | 2026-11-04 | Quarterly Result Announcement | NA | 4.86% |
| 2026-08-05 | 2026-08-05 | Annual General Meeting | NA | -0.83% |
| 2026-08-04 | 2026-08-04 | Quarterly Result Announcement | NA | 1.47% |
| 2026-07-29 | 2026-07-29 | Dividend | ₹ 12.00 /share | 4.12% |
| 2026-05-15 | 2026-05-15 | Quarterly Result Announcement | NA | 4.71% |
| 2026-02-05 | 2026-02-05 | Quarterly Result Announcement | NA | 3.71% |
| 2025-11-04 | 2025-11-04 | Quarterly Result Announcement | NA | -0.92% |
| 2025-08-05 | 2025-08-05 | Annual General Meeting | NA | -1.57% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | -6.22% |
| 2025-07-29 | 2025-07-29 | Dividend | ₹ 11.00 /share | 10.49% |
| 2025-05-06 | 2025-05-06 | Quarterly Result Announcement | NA | 6.54% |
| 2025-02-03 | 2025-02-03 | Quarterly Result Announcement | NA | -9.02% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | -3.68% |
| 2024-07-22 | 2024-07-22 | Annual General Meeting | NA | 27.73% |
| 2024-07-15 | 2024-07-15 | Dividend | ₹ 11.00 /share | -1.72% |
Alembic Pharmaceuticals Competitors Screener - Peer Stocks Comparison
Screen APLLTD competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,076 | 41.10 | 61,674 | 12.69% | 11,565 | 59.98 |
| Divis Laboratories | 294,139 | 90.70 | 11,067 | 13.95% | 2,568 | 67.88 |
| Torrent Pharmaceuticals | 178,438 | 84.50 | 13,886 | 20.34% | 2,138 | 49.31 |
| Laurus Labs | 119,949 | 98.10 | 6,868 | 22.01% | 890 | 49.19 |
| Zydus Life Science | 118,902 | 27.60 | 27,658 | 17.64% | 5,026 | 52.87 |
| Dr Reddys Laboratories | 115,011 | 41.70 | 35,059 | 3.90% | 4,158 | 69.34 |
| Cipla | 112,656 | 39.40 | 29,045 | 2.24% | 3,870 | 55.82 |
| Mankind Pharma | 108,490 | 48.40 | 14,636 | 14.85% | 1,938 | 63.62 |
| Aurobindo Pharma | 103,223 | 26.40 | 34,145 | 5.56% | 3,503 | 60.38 |
| Lupin | 90,393 | 17.30 | 29,039 | 26.75% | 5,356 | 44.23 |
Alembic Pharmaceuticals Company Announcements - News & Reports Screener
Screen APLLTD latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 18, 2026.
The next most recent announcements are dated November 14, 2026 and November 5, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-18 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-11-14 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-11-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-11-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-11-04 | Updated Contact Details Of Key Managerial Personnel Pursuant To Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-11-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-11-04 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-11-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-11-04 | Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026 | - |
| 2026-11-04 | Board Meeting Outcome for Outcome Of Board Meeting Held On 4Th November 2026 | - |
| 2026-11-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-30 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-28 | Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2026. | - |
| 2026-10-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-10-27 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-19 | Intimation Under Regulation 30 Of SEBI LODR Regulations 2015 | - |
| 2026-10-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,049.60, within a 52-week range of ₹646.55 to ₹1,057.10. The P/E ratio is 24.10 and the P/B ratio is 3.40, with earnings per unit of ₹34.33. Market capitalisation stands at ₹20,778.69 Cr and the dividend yield is 1.16%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.